Centers | ||
|
|
|
EU-OPENSCREEN | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Therapeutic Accelerator Program (TAP) |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Test |
Partnerships |
Events |
Jobs |
Eisiai Partners with Johns Hopkins Brain Science InstituteEisiai Partners with Johns Hopkins Brain Science Institute ("BSi") an institute which is part of Johns Hopkins University to develop new drugs for neurological diseases. Under this joint collaboration, BSi will provide validated targets to Eisai... View all XenoTech / XenoGesis
View all GSK and Yale to partner on drug discovery developmentGlaxoSmithKline (GSK) and Yale University will partner to design a new class of molecules to target disease-causing proteins. This is the latest in a string of deals between Yale’s academic researchers and global pharmaceutical companies. View all |
No EVENTS for listing |
No Job Posts |
